Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Sarepta Therapeutics, Inc. (SRPT) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose material facts to the U.S. Food and Drug Administration (“FDA”) as part of a New Drug Application (“NDA”) submission.
On October 27, 2014, Sarepta announced a regulatory update regarding discussions with the FDA related the Company’s NDA submission for marketing approval of eteplirsen. According to Sarepta, the FDA provided direction regarding additional and more specific data required from the NDA submission.
Following this news, Sarepta shares declined by $7.65 per share, more than 32%, closing on October 27, 2014 at $15.91 per share.
If you invested in Sarepta stock or options between April 21, 2014 and October 27, 2014 and would like to discuss your legal rights, please contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Sarepta’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.